Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jinge Zhao

Showing results (41-50 of 97) with videos related to

Pageof 10
Sort By:
Angewandte Chemie (International Ed. in English)|November 20, 2025
PSMA-Triggered Phase Separation of Peptide-Drug Conjugates Enables Zinc-Dependent Tumor InhibitionKai Han, Jian Zhang, Xiaolu Miao, et al.
Therapeutic Advances in Medical Oncology|July 28, 2025
First-line systemic therapy in patients with metastatic or locally advanced urothelial carcinoma: a systematic review and network meta-analysis of randomized controlled trialsYandong Xie, Haoyang Liu, Yanfeng Tang, et al.
Cancer Control : Journal of the Moffitt Cancer Center|December 3, 2020
The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase InhibitorsHaoran Zhang, Xingming Zhang, Xudong Zhu, et al.
Oncology Research|July 7, 2023
Mutations in epigenetic regulator <i>KMT2C</i> detected by liquid biopsy are associated with worse survival in prostate cancer patientsSha Zhu, Nanwei Xu, Jiayu Liang, et al.
Angewandte Chemie (International Ed. in English)|September 11, 2025
Persistent Membrane-Anchored Oligomeric Peptides with Nanopore Formation for Targeted Immune ModulationJingtian Cao, Yao Yu, Kai Han, et al.
Molecular Cancer Therapeutics|May 21, 2020
Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate CancerJinge Zhao, Shu Ning, Wei Lou, et al.
BMC Cancer|January 12, 2019
Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinomaXingming Zhang, Xiaoxue Yin, Haoran Zhang, et al.
Frontiers in Oncology|May 24, 2023
Primary renal mucinous adenocarcinoma masquerading as a giant renal cyst: a case reportHong Zeng, Mengni Zhang, Yandong Xie, et al.
Urologic Oncology|October 15, 2018
What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysisGuangxi Sun, Xingming Zhang, Junru Chen, et al.
Japanese Journal of Clinical Oncology|July 29, 2020
The influence of dynamic changes in lipid metabolism on survival outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitorsXingming Zhang, Haoran Zhang, Jindong Dai, et al.
Pageof 10

Showing results (41-50 of 97) with videos related to

Sort By:
Pageof 10
Angewandte Chemie (International Ed. in English)|November 20, 2025
PSMA-Triggered Phase Separation of Peptide-Drug Conjugates Enables Zinc-Dependent Tumor InhibitionKai Han, Jian Zhang, Xiaolu Miao, et al.
Therapeutic Advances in Medical Oncology|July 28, 2025
First-line systemic therapy in patients with metastatic or locally advanced urothelial carcinoma: a systematic review and network meta-analysis of randomized controlled trialsYandong Xie, Haoyang Liu, Yanfeng Tang, et al.
Cancer Control : Journal of the Moffitt Cancer Center|December 3, 2020
The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase InhibitorsHaoran Zhang, Xingming Zhang, Xudong Zhu, et al.
Oncology Research|July 7, 2023
Mutations in epigenetic regulator <i>KMT2C</i> detected by liquid biopsy are associated with worse survival in prostate cancer patientsSha Zhu, Nanwei Xu, Jiayu Liang, et al.
Angewandte Chemie (International Ed. in English)|September 11, 2025
Persistent Membrane-Anchored Oligomeric Peptides with Nanopore Formation for Targeted Immune ModulationJingtian Cao, Yao Yu, Kai Han, et al.
Molecular Cancer Therapeutics|May 21, 2020
Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate CancerJinge Zhao, Shu Ning, Wei Lou, et al.
BMC Cancer|January 12, 2019
Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinomaXingming Zhang, Xiaoxue Yin, Haoran Zhang, et al.
Frontiers in Oncology|May 24, 2023
Primary renal mucinous adenocarcinoma masquerading as a giant renal cyst: a case reportHong Zeng, Mengni Zhang, Yandong Xie, et al.
Urologic Oncology|October 15, 2018
What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysisGuangxi Sun, Xingming Zhang, Junru Chen, et al.
Japanese Journal of Clinical Oncology|July 29, 2020
The influence of dynamic changes in lipid metabolism on survival outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitorsXingming Zhang, Haoran Zhang, Jindong Dai, et al.
Pageof 10